<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831047</url>
  </required_header>
  <id_info>
    <org_study_id>20210199</org_study_id>
    <nct_id>NCT04831047</nct_id>
  </id_info>
  <brief_title>The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance</brief_title>
  <official_title>The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Palpebral Fissure Height, Eye Redness, and Patient-reported Eye Appearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to see if Upneeq ( oxymetazoline 0.1% ophthalmic solution) has&#xD;
      an effect on eyelid position, eye redness, or patient-perceived appearance of the eyes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in palpebral fissure height</measure>
    <time_frame>Baseline, Day 1</time_frame>
    <description>Palpebral fissure height will be calculated from the sum of marginal reflex distance 1 and 2 measured from the photograph by Ipad software and recorded by investigators before and after drop instillation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in eye redness</measure>
    <time_frame>Baseline, Day 1</time_frame>
    <description>Scoring of ocular redness from clinical photographs will be performed by investigators on a 0 - 4 unit scale as compared to standardized reference photographs (0 = no redness, 4 = very red) before and after drop instillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported eye appearance</measure>
    <time_frame>Day 1</time_frame>
    <description>Patient-reported eye appearance will be assessed by patient completion of the FACE-Q Eye Module Survey. FACE-Q includes 4 scales, each with a sum score of 7 (worst) to 28 (best) which is converted to a scale summed score from 0 (worst) to 100 (best). These scale scores will be assessed individually and averaged to determine the total Eye Module Survey score from 0 (worst) to 100 (best).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Ptosis, Eyelid</condition>
  <condition>Conjunctiva Inflamed</condition>
  <condition>Eye Manifestations</condition>
  <arm_group>
    <arm_group_label>Upneeq Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive a one-time dosing of oxymetazoline hydrochloride 0.1% (1 drop applied to ocular surface of each eye of patients in the treatment group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants in this group will receive a one-time dosing of balanced saline solution (1 drop applied to ocular surface of each eye of patients in the control group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymetazoline hydrochloride 0.1% ophthalmic solution</intervention_name>
    <description>One drop of Upneeq (Oxymetazoline hydrochloride 0.1% ophthalmic solution) will be applied to the ocular surface of each eye.</description>
    <arm_group_label>Upneeq Group</arm_group_label>
    <other_name>Upneeq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Balanced saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults age 18 and above able to provide informed consent to participate&#xD;
&#xD;
          -  Subject with stable ocular health, defined as no ocular conditions requiring ongoing&#xD;
             topical therapy or recent surgical intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Individuals less than 18 years of age&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Known contradictions or sensitivities to study medication (oxymetazoline)&#xD;
&#xD;
          -  Ocular surgery within the past 3 months or refractive surgery within the past six&#xD;
             months&#xD;
&#xD;
          -  Grossly abnormal lid margins, anatomical abnormalities, previous eyelid or orbital&#xD;
             surgery&#xD;
&#xD;
          -  Variable ptosis or eyelid position (e.g., myasthenia gravis, thyroid eye disease, or&#xD;
             blepharospasm)&#xD;
&#xD;
          -  Any ocular or systemic condition that, in the opinion of the investigator, would&#xD;
             confound study data, interfere with the subject's study participation, or affected the&#xD;
             subject's safety or trial parameters&#xD;
&#xD;
          -  Presence of an active ocular infection&#xD;
&#xD;
          -  Prior (within 5 days of beginning study treatment) use of eye whiteners (eg,&#xD;
             vasoconstrictors), decongestants, antihistamines (including over the counter and&#xD;
             herbal topical ophthalmic medications), phenylephrine dilating drops, any other&#xD;
             topical ophthalmic agents&#xD;
&#xD;
          -  Inability to sit comfortably for 15 - 30 minutes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy W. Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy W. Lee, MD</last_name>
    <phone>305-326-6434</phone>
    <email>wlee@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Shoji, MD</last_name>
      <phone>617-981-1134</phone>
      <email>mshojimd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wendy W Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Wendy Lee</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology and Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharoptosis</mesh_term>
    <mesh_term>Eye Manifestations</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

